Petri Dish Reports

Biotechnology KMDA Petri Dish Reports Uncategorized

Kamada’s Pipeline And Biosimilars Set Stage For Future Earnings Expansion

Mar 13, 2026

ALEC Biotechnology Petri Dish Reports Uncategorized

Alector Stock Jumps On Upgrade, But AL101 Interim Data Will Be Key

Mar 11, 2026

Biotechnology CAMP Petri Dish Reports Uncategorized

Camp4 Therapeutics: Strong Cash Runway As CMP-002 Moves Toward Human Trials

Mar 7, 2026

ALT Biotechnology Petri Dish Reports Uncategorized

Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away

Mar 6, 2026

ABUS Biotechnology MRNA Petri Dish Reports ROIV Uncategorized

Why Moderna’s $950M Patent Bill Is A Small Price For Pipeline Freedom

Mar 4, 2026

Biotechnology Petri Dish Reports Uncategorized ZYME

Zymeworks FY25 Review: From Milestone Volatility To 2026 Upside

Mar 4, 2026

Biotechnology EBS Petri Dish Reports Uncategorized

Emergent BioSolutions Earnings: Revenue, Margins, And GAAP Losses Paint A Mixed Picture

Feb 28, 2026

ARDX Biotechnology Petri Dish Reports Uncategorized

Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability

Feb 20, 2026

Biotechnology Petri Dish Reports Uncategorized VNDA

Vanda Pharma: High Risk, Heavily Discounted – Stock Ahead Of PDUFA This Week

Feb 19, 2026

Biotechnology IRON Petri Dish Reports Uncategorized

Disc Medicine After The CRL: Risk Now Rests On APOLLO

Feb 17, 2026